中国麻风皮肤病杂志 ›› 2021, Vol. 37 ›› Issue (10): 653-656.doi: 10.12144/zgmfskin202110653

• 临床研究 • 上一篇    下一篇

司库奇尤单抗治疗红皮病型银屑病一例并文献复习

朱慧英1,2,施仲香2,曹楠2,田洪青1,2,杜东红2    

  1. 1山东第一医科大学（山东省医学科学院），济南，250002；2山东第一医科大学附属皮肤病医院（山东省皮肤病医院，山东省皮肤病性病防治研究所），济南，250022
  • 出版日期:2021-10-25 发布日期:2021-08-31
  • 通讯作者: 杜东红，E-mail: dudh2010@126.com

Secukinumab in the treatment of erythrodermic psoriasis: a case report and literature review

ZHU Huiying1,2, SHI Zhongxiang2, CAO Nan2, TIAN Hongqing1,2, DU Donghong2   

  1. 1 Shandong First Medical University (Shandong Academy of Medical Sciences), Jinan 250002, China; 2 Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venereology, Shandong First Medical University, Jinan 250022, China
  • Online:2021-10-25 Published:2021-08-31
  • Contact: DU Donghong, E-mail: dudh2010@126.com

PDF (PC)

215

摘要： 报道一例司库奇尤单抗治疗红皮病型银屑病治疗效果并复习相关文献。41岁红皮病型银屑病男性患者，在排除肝炎、结核的基础上，经知情同意后，给予司库奇尤单抗标准方案：0~4周每周皮下注射300 mg，随后每4周注射300 mg。在第4周达到PASI 75，第8周达到PASI 100。随访32周未见明显复发及不良反应。

关键词: 红皮病型银屑病, 司库奇尤单抗, 银屑病, 生物制剂, 抗IL-17A

Abstract: A 41-year-old male with erythrodermic psoriasis treated with secukinumab was reported and the related literature were reviewed. After excluding hepatitis and tuberculosis, the patient was given the secukinumab with informed consent. The dose was 300 mg subcutaneously once a week in the first 4 weeks, then 300 mg once every four weeks. The PASI achieved to 75% at week 4 and 100% at week 8. There was no recurrence and adverse events after 32 weeks follow-up.

Key words: erythrodermic psoriasis, secukinumab, psoriasis, biologics, anti-IL17A